Twice-yearly lenacapavir is a major biomedical advance, but clinical efficacy alone will not deliver population-level HIV prevention impact. The immediate policy challenge is to convert exceptional...
No takes yet. Share an insight, caveat, or question.
Omar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: